David O'Malley's guest appearances

David O'Malley

The James Cancer-Free World Podcast

Oncology Today with Dr Neil Love

Radio Maria England

John Bosco

Peter Harris

Teresa Benedicta

Gary Stevens

John Bradburne

Mary Johnson

Eric Liddell

Joanna Bogle

Sam Baker

Philip Howard

Robert Thomas

Paul Grogan

Julian of Norwich

Philip Egan

Joseph Church

OwlTail

“I like to say that patients at the James have access to tomorrow’s therapies today,” said David O’Malley, MD, the director of the James Division of Gynecologic Oncology and Co-Director of the Gyn Oncology Phase I Program. In this episode, O’Malley describes a new clinical trial that provides “tomorrow’s therapies today” to patients at the James, and beyond. A clinical trial led by O’Malley utilizes two immunotherapy agents to treat women with advanced or recurrent cervical cancer. In the past, there were limited treatment options for these patients. The first drug, balstilimab, allows the immune system of a patient to recognize cancer cells that had previously been able to camouflage themselves and hide from the immune system. The second drug, zalifrelimab helps the body’s tired iimmune cells “reinvigorate themselves to better get to and fight those cancer cells,” O’Malley explains. In a James-led, Phase 2 clinical trial of 125 patients in the United States and beyond “we tripled the response rates,” O’Malley said. “And, not only was there better response rates, but the durability is more pronounced, and when I look at patients two years out, they’re still responding.”The advances made possible by immunotherapy agents and clinical trials are accelerating at a rapid rate. This has O’Malley optimistic about the future. “We’re in an unprecedented time in cancer treatment and drug development,” he said. “I’m seeing things today I really didn’t think I’d live to see,”

“I like to say that patients at the James have access to tomorrow’s therapies today,” said David O’Malley, MD, the director of the James Division of Gynecologic Oncology and Co-Director of the Gyn Oncology Phase I Program. In this episode, O’Malley describes a new clinical trial that provides “tomorrow’s therapies today” to patients at the James, and beyond. A clinical trial led by O’Malley utilizes two immunotherapy agents to treat women with advanced or recurrent cervical cancer. In the past, there were limited treatment options for these patients. The first drug, balstilimab, allows the immune system of a patient to recognize cancer cells that had previously been able to camouflage themselves and hide from the immune system. The second drug, zalifrelimab helps the body’s tired iimmune cells “reinvigorate themselves to better get to and fight those cancer cells,” O’Malley explains. In a James-led, Phase 2 clinical trial of 125 patients in the United States and beyond “we tripled the response rates,” O’Malley said. “And, not only was there better response rates, but the durability is more pronounced, and when I look at patients two years out, they’re still responding.” The advances made possible by immunotherapy agents and clinical trials are accelerating at a rapid rate. This has O’Malley optimistic about the future. “We’re in an unprecedented time in cancer treatment and drug development,” he said. “I’m seeing things today I really didn’t think I’d live to see,”

Episode 107: Advances in Cervical Cancer Treatment with Immunotherpay, with Dr. David O'Malley

with Fr. David O'Malley and Stephen Lloyd.

with Fr. David O'Malley and Stephen Lloyd.

Catechesis - St. John Bosco – with Fr. David O'Malley and Stephen Lloyd – 2022.01.31

Dr David O’Malley from the Ohio State University and The James Cancer Center in Columbus discusses the current and future roles of immune checkpoint inhibitors and other novel therapies in the management of gynecologic cancers. CME information and select publications here.

Dr David O’Malley from the Ohio State University and The James Cancer Center in Columbus discusses the current and future roles of immune checkpoint inhibitors and other novel therapies in the management of gynecologic cancers. CME information and select publications <a href="https://www.researchtopractice.com/OncologyTodaySGOImmuno20" rel="nofollow" target="_blank">here</a>.

Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in the Management of Gynecologic Cancers with Dr David O'Malley